Aurora Therapeutics has emerged from stealth with $16 million in funding from Menlo Ventures to expand the potential of gene ...

A stretch of viral DNA in the mouse genome gives cells in early-stage embryos the potential to become almost any cell type in ...

Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has ...

The firm expects its $1.25 billion cash runway to cover operating and capital expenses through 2029, including development plans for key assets.

Machine learning models reveal that histone marks are predictive of gene expression across human cell types and highlight important nuances between natural control and the effects of CRISPR-Cas9-based ...

A UK startup aiming to solve key challenges in life sciences through AI has unveiled the “world’s first AI models for ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...

Friday, Aurora Therapeutics debuted with $16 million in seed capital from Menlo Ventures. Its goal: To develop the industry’s ...

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

A large genetic screen has revealed how stem cells transform into brain cells, exposing hundreds of genes that make this ...

Gene-editing technologies show great promise for medical treatments and research, with the potential to cure thousands of ...

A notable surge in investment activity has emerged around Intellia Therapeutics, with significant share acquisitions by both ...